U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H31N3O2S
Molecular Weight 425.5888
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARPHENAZINE

SMILES

CCC(=O)c1ccc2c(c1)N(CCCN3CCN(CC3)CCO)c4ccccc4S2

InChI

InChIKey=XZSMZRXAEFNJCU-UHFFFAOYSA-N
InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3

HIDE SMILES / InChI

Molecular Formula C24H31N3O2S
Molecular Weight 425.5888
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://edudrugs.com/P/Proketazine/more.html | https://en.wikipedia.org/wiki/Carfenazine | https://www.ncbi.nlm.nih.gov/pubmed/14267601

Carfenazine (brand name Proketazine) is an antipsychotic and tranquilizer of the phenothiazine group. It is used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients. Proketazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. The following is a list of possible side effects that may occur from all constituting ingredients of Proketazine: akathisia, tardive dyskinesia, extrapyramidal symptoms, allergic purpura.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROKETAZINE

Approved Use

Used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients.
Doses

Doses

DosePopulationAdverse events​
100 mg 4 times / day steady, oral
Dose: 100 mg, 4 times / day
Route: oral
Route: steady
Dose: 100 mg, 4 times / day
Sources:
unhealthy, 18 - 60 years
Health Status: unhealthy
Age Group: 18 - 60 years
Sex: F
Sources:
Disc. AE: Skin rash...
Other AEs: Faintness...
AEs leading to
discontinuation/dose reduction:
Skin rash (grade 4, 1 patient)
Other AEs:
Faintness (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Faintness 1 patient
100 mg 4 times / day steady, oral
Dose: 100 mg, 4 times / day
Route: oral
Route: steady
Dose: 100 mg, 4 times / day
Sources:
unhealthy, 18 - 60 years
Health Status: unhealthy
Age Group: 18 - 60 years
Sex: F
Sources:
Skin rash grade 4, 1 patient
Disc. AE
100 mg 4 times / day steady, oral
Dose: 100 mg, 4 times / day
Route: oral
Route: steady
Dose: 100 mg, 4 times / day
Sources:
unhealthy, 18 - 60 years
Health Status: unhealthy
Age Group: 18 - 60 years
Sex: F
Sources:
PubMed

PubMed

TitleDatePubMed
Carphenazine in the intensive care of chronically ill psychotics.
1967 Aug
Evaluation of carphenazine in hospitalized schizophrenic women.
1967 Feb
Carphenazine in the treatment of schizophrenic psychoses. Controlled clinical trial.
1967 Nov
Patents

Sample Use Guides

First week, 25 mg. t.i.d.; second week, 50 mg. t.i.d.; third week, 75 mg. t.i.d.; fourth week, 100 mg. t.i.d.; fifth week and thereafter, 100 mg. q.i.d.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:46:00 UTC 2021
Edited
by admin
on Fri Jun 25 23:46:00 UTC 2021
Record UNII
CLY16Y8Z7E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARPHENAZINE
MI  
Common Name English
CARPHENAZINE [MI]
Common Name English
CARFENAZINE
INN   WHO-DD  
INN  
Official Name English
CARFENAZINE [INN]
Common Name English
CARFENAZINE [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29710
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
Code System Code Type Description
CAS
2622-30-2
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
DRUG CENTRAL
516
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
DRUG BANK
DB01038
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
NCI_THESAURUS
C73285
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
MERCK INDEX
M1057
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
220-072-9
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
FDA UNII
CLY16Y8Z7E
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201328
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
IUPHAR
7140
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
EPA CompTox
2622-30-2
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
INN
1179
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
PUBCHEM
18104
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
EVMPD
SUB06625MIG
Created by admin on Fri Jun 25 23:46:00 UTC 2021 , Edited by admin on Fri Jun 25 23:46:00 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY